Cartesian Therapeutics (RNAC) Net Cash Flow (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Net Cash Flow data on file, last reported at -$6.5 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$6.5 million, up 79.85% year-over-year; the trailing twelve-month figure through Mar 2026 was -$61.7 million (down 179.87% YoY), and the FY2025 annual result was -$87.4 million, down 164.3% from the prior year.
• Net Cash Flow climbed to -$6.5 million in Q1 2026 per RNAC's latest filing, from -$18.3 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $132.0 million in Q3 2024 and troughed at -$34.0 million in Q3 2023.
• A 5-year average of $291529.4 and a median of -$6.6 million in 2024 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 7416.87% in 2022 and fell as far as 992.78% in 2022.
• A 5-year view of Net Cash Flow shows it stood at -$6.4 million in 2022, then jumped by 57.42% to -$2.7 million in 2023, then tumbled by 142.73% to -$6.6 million in 2024, then plunged by 177.74% to -$18.3 million in 2025, then soared by 64.44% to -$6.5 million in 2026.
• Business Quant data shows RNAC's Net Cash Flow at -$6.5 million in Q1 2026, -$18.3 million in Q4 2025, and -$16.9 million in Q3 2025.